Imunon, Inc. (NASDAQ:IMNN – Get Rating) fell 1.8% during mid-day trading on Friday . The stock traded as low as $1.29 and last traded at $1.35. 43,140 shares traded hands during trading, a decline of 64% from the average session volume of 119,455 shares. The stock had previously closed at $1.38.
Analyst Upgrades and Downgrades
A number of equities analysts have commented on IMNN shares. Brookline Capital Management reiterated a "buy" rating on shares of Imunon in a report on Monday, November 14th. Alliance Global Partners initiated coverage on shares of Imunon in a research report on Thursday, October 13th. They issued a "buy" rating and a $15.00 target price for the company.
Get Imunon alerts:Imunon Price Performance
The company has a debt-to-equity ratio of 0.13, a quick ratio of 4.75 and a current ratio of 4.75. The company's 50-day moving average is $1.44.
Imunon (NASDAQ:IMNN – Get Rating) last posted its earnings results on Monday, November 14th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.81) by ($0.06). The firm had revenue of $0.13 million during the quarter, compared to analyst estimates of $0.11 million. Imunon had a negative net margin of 5,377.20% and a negative return on equity of 56.47%. As a group, research analysts forecast that Imunon, Inc. will post -4.14 earnings per share for the current year.Imunon Company Profile
(Get Rating)
Imunon, Inc, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications.
Recommended Stories
- Get a free copy of the StockNews.com research report on Imunon (IMNN)
- MarketBeat: Week in Review 12/26 – 12/30
- The Dogs Of Tech: It's Time For A Bite Of These Stocks
- Does This Acquisition Make Microsoft a Bear Market Buy?
- Should You Warm up to Generac Stock for the Winter?
- Is Kintara Therapeutics A Hidden Gem?
Receive News & Ratings for Imunon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imunon and related companies with MarketBeat.com's FREE daily email newsletter.